



St Cloud, le 21 mars 2022

COMMUNIQUE DE PRESSE

Vectans Pharma is pleased to announce the nomination of François Boutignon as Chief Innovation and Technology Officer.

With a focus on anti-infective drugs and supportive care, Vectans Pharma optimizes existing treatments and develops innovative medicine through its Lauriad® Technology.

François Boutignon is also President and CEO of Aptys Pharma, a company specialized in formulation design and development.

Prior to launching Aptys Pharma in 2002, François was vice-president of R&D at Europeptides, a subsidiary of Asta Medica.

He is the author of more than fifty papers and communications, and the person behind ten patents.

François will bring his know-how and his expertise on innovative drug delivery technologies, to support Vectans redesigning medicines.